Zobrazeno 1 - 10
of 14
pro vyhledávání: '"L Velasco Roces"'
Autor:
L Macía-Rivas, L Velasco-Roces, CL Fernandez-Laguna, C Álvarez-Asteinza, M Maray, S Fernández Lastras, DLFV Irene, L Oyague López, M Eiroa Osorio, A Lozano Blázquez
Publikováno v:
Section 4: Clinical pharmacy services.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::652b6f4dde02a16c538b0d34aaa66060
https://doi.org/10.1136/ejhpharm-2022-eahp.95
https://doi.org/10.1136/ejhpharm-2022-eahp.95
Autor:
MC Rosado María, L Velasco Roces, C Álvarez Asteinza, A Lozano Blázquez, I Maray Mateos, A. Martínez, V García Jimenez, B Zarate Tamames, Á Pieras López, CL Fernández Laguna, R Menárguez Blanc
Publikováno v:
Section 5: Patient Safety and Quality assurance.
Background and importance Antifibrotics are an important alternative for the treatment of idiopathic pulmonary fibrosis (IPF) but long term follow-up studies of their effectiveness and safety are required. Aim and objectives To assess the safety and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d72af617a5efc9d5ce67f19c64d4c3e7
https://doi.org/10.1136/ejhpharm-2020-eahpconf.420
https://doi.org/10.1136/ejhpharm-2020-eahpconf.420
Autor:
CL Fernández Laguna, R Menárguez Blanc, I Maray Mateos, B Zarate Tamames, L Velasco Roces, C Álvarez Asteinza, Á Pieras López, A. Martínez, L Macía Rivas, A Lozano Blázquez, A Rodríguez Ferreras
Publikováno v:
Section 6: Education and Research.
Background and importance The proprotein convertase subtilisin kexin type 9 inhibitors (PCSK9i), evolocumab and alirocumab, approved by the European Medicines Agency in 2015, are a new approach in obtaining a large reduction in serum low density lipo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::fea13717acd2f569aca2541ad8a36a39
https://doi.org/10.1136/ejhpharm-2020-eahpconf.436
https://doi.org/10.1136/ejhpharm-2020-eahpconf.436
Autor:
Á Pieras López, E Lázaro López, B Zarate Tamames, A Lozano Blázquez, I Maray Mateos, L Ordóñez Fernández, L Velasco Roces, C Álvarez Asteinza, A Rodríguez Ferreras
Publikováno v:
Section 4: Clinical Pharmacy Services.
Background Dupilumab is an Interleukin-4 receptor antagonist approved for the treatment of moderate-severe atopic dermatitis (AD) in patients not candidates or refractory to systemic therapy. Dupilumab is not commercialised in Spain so patients must
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::dc8e5cff5a37df539460fe8314105a07
https://doi.org/10.1136/ejhpharm-2019-eahpconf.188
https://doi.org/10.1136/ejhpharm-2019-eahpconf.188
Publikováno v:
Section 4: Clinical Pharmacy Services.
Background Linezolid is a broad-spectrum antibiotic active against gram-positive bacteria and its use must be controlled. The definite daily dose (DDD) is a statistical measure of drug consumption: the assumed average maintenance dose per day for a d
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::832c7bfd513402dc92aee1598e66cd4b
https://doi.org/10.1136/ejhpharm-2019-eahpconf.405
https://doi.org/10.1136/ejhpharm-2019-eahpconf.405
Autor:
Á Pieras López, C Carriles Fernandez, E Lázaro López, I Zapico García, L Velasco Roces, A Rodríguez Ferreras, R Menárguez Blanc, B Zarate Tamames, A Lozano-Blázquez, A. Martínez
Publikováno v:
Eur J Hosp Pharm
Background Dense deposit disease (DDD) is a rare glomerulonephritis caused by uncontrolled stimulation of the alternative complement pathway. Allograft survival after kidney transplantation is significantly reduced by the high rate of disease recurre
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2638073373137ecaece387b5a2e49962
https://europepmc.org/articles/PMC7535363/
https://europepmc.org/articles/PMC7535363/
Autor:
MC Rosado María, C Carriles Fernandez, R Menárguez Blanc, A Arias, A Martinez Torron, A Lozano-Blázquez, I Zapico García, L Velasco Roces
Publikováno v:
Eur J Hosp Pharm
Background Alemtuzumab is a monoclonal antibody directed against the CD52 antigen on T- and B-lymphocytes indicated in adult patients with relapsing remitting multiple sclerosis (RRMS). Purpose To assess safety, reason for switching, compliance with
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::70ef2ae67829c39122f298c72d6b6749
https://doi.org/10.1136/ejhpharm-2018-eahpconf.257
https://doi.org/10.1136/ejhpharm-2018-eahpconf.257
Autor:
E Lázaro López, L Velasco Roces, L Gómez de Segura Iriarte, A Rodríguez Ferreras, MT Iglesias Garcia, L Suárez Fernández
Publikováno v:
Other hospital pharmacy topics.
Background New technologies are introduced frequently in healthcare and change professionals’ perceptions of quality of life. Purpose To assess the impact on professionals’ quality of life in a hospital pharmacy department, 2 years after transfer
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::58c32a7f4458ab7bb171f056a6033e8b
https://doi.org/10.1136/ejhpharm-2017-000640.428
https://doi.org/10.1136/ejhpharm-2017-000640.428
Autor:
C Carriles Fernandez, C Rosado María, L Rodríguez Ferreras, E Lázaro López, L Velasco Roces, A Gómez de Segura Iriarte
Publikováno v:
Drug information and pharmacotherapy.
Background TAS-102 is an oral agent that combines trifluridine and tipiracil hydrochloride. Trifluridine is the active cytotoxic component with antitumour effects and tipiracil is an inhibitor that prevents the rapid degradation of trifluridine. The
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b06074472a8a59c60161204c2c6f9fe4
https://doi.org/10.1136/ejhpharm-2017-000640.311
https://doi.org/10.1136/ejhpharm-2017-000640.311
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.